9th March 2023
EIT Health partnered with the European Innovation Council (EIC) for a year-long pilot collaboration that sought to create synergies between the two organisations for the purpose of enhancing Europe’s support of innovation and breakthrough technologies in healthcare.
One core element of the collaboration was channelling EIC-supported ventures into relevant EIT Health programmes and events by amplifying programme offerings between the two institutions. Start-ups eligible for such offerings had received funding through participation in EIC programmes.
Several outstanding start-ups supported through the project have demonstrated some important achievements within the implementation period of this pilot project. There have been a number of successes and synergies achieved during the project but the stories of three start-ups stand out.
PubGene is a personalised medicine solution for better diagnosis and treatment, utilising a mix of trusted technological sources, the patient’s own genetic and biomedical data, natural language processing and AI technology.
During the project, PubGene secured €1.1M in investment and completed a successful market access analysis of their product in the UK. The start-up also stepped out of its home market and validated its solution in one of the biggest European markets.
When asked about his experience of this pilot project, Jeremy McCrohan, CFO of PubGene said: “We found the programme and the catalyser(s) we used were terrific. We learned a lot about our company and the market, and are very happy to have participated.”
BestHealth4U develops next-generation technologies for skin-interacting medical devices that improve one’s health and quality of life, maintaining healthy skin by using sustainable biomaterials.
The start-up successfully raised €1M in a seed round, worked on new market validation in both China and the US, and actively participated in our different programmes to address the company’s needs.
Qubiotech is developing an automatic and multimodal medical-imaging processing software to improve routine healthcare processes with quantitative biomarkers and integrate daily clinical workflow.
The start-up attracted €210k investment and participated in several EIT Health programmes to validate the UK market and continue to strengthen its investment readiness. Daniel Fernandez Mosquera, CEO of Qubiotech Health Intelligence SL said: “The training helped me get more confidence on financial issues.”
How can young scientists move to innovation roles?
Q&A with Carmen Schweicker
EIT Health named top business accelerator by UBI Global
Learn more about the achievement
Arthex Biotech closes a €42M Series B financing round
Find out more about our support